Funding for this research was provided by:
National Institute of General Medical Sciences (T32GM088129)
National Institute of Dental and Craniofacial Research (F31DE026682, DE023577, U01DE028233)
National Center for Advancing Translational Sciences (KL2TR001874)
Received: 16 April 2019
Accepted: 31 July 2019
First Online: 13 August 2019
Ethics approval and consent to participate
: All mice were housed and treated in accordance with Institutional Animal Care and Use Committee guidelines at Baylor College of Medicine.
: Not applicable.
: RDG-C has received travel support from PerkinElmer and has consulted on an advisory board for Northwest Biotherapeutics. AGS receives support in the form of investigational drug from Advaxis for an investigator-initiated clinical trial. AGS receives funds for clinical trial development from Tessa Therapeutics in the form of grant support.